重症病毒性肺炎免疫紊乱与糖皮质激素治疗研究进展  

Research progress in immune disorders and glucocorticoid therapy in severe viral pneumonia

作　　者：石林勇 于雪聪 杜倩茹 王耀勇 SHI Linyong;YU Xuecong;DU Qianru;WANG Yaoyong(Fenyang College of Shanxi Medical University,Fenyang,Shanxi,032200;Department of Respiratory and Critical Care Medicine,Fenyang Hospital of Shanxi Province,Fenyang,Shanxi,032200)

机构地区：[1]山西医科大学汾阳学院,山西汾阳032200 [2]山西省汾阳医院呼吸与危重症医学科,山西汾阳032200

出　　处：《实用临床医药杂志》2025年第6期139-142,148,共5页Journal of Clinical Medicine in Practice

基　　金：山西省卫生健康委员会科研项目(2023XG113);山西省吕梁市引进高层次科技人才重点研发项目(2021RC-2-31)。

摘　　要：免疫功能紊乱在重症病毒性肺炎的发病机制及疾病进程中扮演重要角色。免疫反应过度激活或免疫抑制状态,均可能对患者的临床结局产生不利影响。糖皮质激素作为广泛应用的免疫调节药物,在重症病毒性肺炎的治疗中占据重要地位。深入探讨重症病毒性肺炎患者体内复杂的免疫紊乱机制、精确评估个体化免疫状态,并据此制订糖皮质激素及其他免疫干预措施的优化方案,对于提升此类患者的救治成功率至关重要。本文综述重症病毒性肺炎免疫紊乱与糖皮质激素治疗研究进展,为临床实践提供理论支持,以改善重症病毒性肺炎患者的预后。Immune dysfunction plays a pivotal role in the pathogenesis and progression of severe viral pneumonia.Both hyperactivated immune responses and immunosuppressive states may adversely affect clinical outcomes.Glucocorticoids,widely utilized as immunomodulatory agents,hold significant therapeutic value in managing this condition.Elucidating the intricate mechanisms underlying immune dysregulation in these patients,accurately assessing individualized immune profiles,and optimizing glucocorticoid regimens alongside other immunomodulatory interventions are critical to improving clinical success rates.This review synthesized current progress in research on immune disorders and glucocorticoid therapy in severe viral pneumonia,providing theoretical foundations for clinical practice to enhance patient prognosis.

关 键 词：重症病毒性肺炎 免疫功能紊乱 糖皮质激素 免疫调节药物 免疫评估 发病机制 呼吸道病毒 免疫紊乱 

分 类 号：R563.1[医药卫生—呼吸系统] R392.32[医药卫生—内科学] R459.1[医药卫生—临床医学]